Database / Oral semaglutide 25 mg
Oral semaglutide 25 mg*
Wegovy pill · Novo Nordisk. The Wegovy molecule in a daily tablet, matching the injection's weight loss. Must be taken fasting with a sip of water and a 30-minute wait.
Average weight loss
16.6%
Stopped for side effects
6.9%
Trial length
64 wk
Ranking score
4.6
* Wegovy pill: small trial with dose reductions. OASIS 4 included 307 adults, only about 205 of them on the pill, against 1,961 in STEP 1 for the injection, so its side-effect rates are less reliable. In addition, 18.6% of participants who completed treatment ended on a lower dose than 25 mg, which probably kept some from stopping and lowered the reported 6.9% discontinuation rate. Its ranking against the injection should be treated as provisional.
OASIS 4 results
Phase 3 · 64 weeks · 25 mg daily
Adults with obesity or overweight, no diabetes (n=307; about 205 on the pill)
Weight loss
16.6%
Nausea
46.6%
Vomiting
30.9%
Diarrhea
17.6%
Constipation
20.1%
Quit due to side effects
6.9%
n/r = not reported. Counting everyone who started, weight loss was 13.6%. Placebo group: 2.2%.
Worth knowing
- Label includes heart attack and stroke risk reduction.
4.6
GLP-1 Performance Index
Rank 4 of 6 ranked drugs
Stomach = (46.6 + 30.9 + 17.6 + 20.1) ÷ 4
= 28.8
Burden = 28.8 + 1 × 6.9 = 35.7
Index = 16.6 ÷ 35.7 × 10 = 4.65
At a glance
- Company
- Novo Nordisk
- Targets
- GLP-1
- Molecule
- Peptide
- Dosing
- Oral, daily
- Status
- FDA approved (Dec 22, 2025)
Sources
History
- FDA approves the Wegovy pill (oral semaglutide 25 mg).